首页 > 市场调查报告书 > 製药

糖尿病

市场调查报告书

商品编码

1620197

糖尿病足溃疡的全球市场规模：按治疗类型、设备、最终用户和地区划分

Global Diabetic Foot Ulcers Market Size By Type of Treatment, By Devices, By End-users, And By Geography

出版日期: 2024年08月25日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

糖尿病足溃疡市场规模及预测

2023 年糖尿病足溃疡市场规模为 15.3 亿美元，预计到 2030 年将达到 31 亿美元，预计 2024-2031 年复合年增长率为 9.24%。

糖尿病足溃疡的全球市场推动因素

糖尿病足溃疡市场的市场推动因素可能受到多种因素的影响。

糖尿病盛行率增加：

随着全球糖尿病盛行率的增加，糖尿病足溃疡的盛行率也在增加。由于糖尿病患者人数不断增加以及足部溃疡等併发症的风险增加，对糖尿病的治疗和管理方法的需求不断增长。

人口老化：

糖尿病及其后果（例如糖尿病足溃疡）在老年族群中更为常见。随着人口老化，面临 DFU 风险的人数增加，这是市场扩张的驱动力。

技术进步：

随着伤口治疗技术的进步，包括改进的敷料、负压伤口治疗和生物工程皮肤替代品，糖尿病足溃疡的治疗和结果正在改善。这些技术的采用降低了截肢风险并提高了治癒率，从而推动了市场扩张。

政府计画：

DFU 市场主要由政府旨在减轻糖尿病及其併发症负担的计划推动。随着政策强调糖尿病教育、预防和获得医疗保健服务，对 DFU 治疗的需求可能会增加。

医疗支出增加：

医疗保健支出的增加将有可能改善糖尿病足溃疡的治疗和管理方案，特别是在新兴国家。随着越来越多的人和医疗机构投入资源来控製糖尿病及其影响，DFU 市场将会成长。

意识计画：

透过教育人们足部护理对糖尿病患者的重要性，医疗机构、患者权益团体和製药公司可以鼓励足部溃疡的早期发现和治疗，这将对市场产生积极影响。糖尿病足溃疡可导致感染和下肢截肢等严重併发症，进而导致巨大的医疗费用和经济压力。透过有效的管理和治疗计划来解决这些问题已变得至关重要，从而增加了对 DFU 产品和服务的需求。

联合研发：

製药公司、学术机构和医疗保健提供者之间的合作正在开发糖尿病足溃疡的新治疗方法和干预措施。这些合作关係加快了研发步伐，从而推出了新颖的产品和治疗方法并扩大了市场。

限制全球糖尿病足溃疡市场的因素

有几个因素可能会成为糖尿病足溃疡市场的限制和课题。其中包括：

治疗费用高：

糖尿病足溃疡的治疗费用可能很高，因为需要持续就诊、使用专业伤口护理产品，有时还需要手术。患者可能会发现自己陷入财务困难，特别是如果他们的医疗保险有限。

医疗基础设施不足：

许多地区，特别是贫穷国家，没有足够的医疗保健基础设施或接受过糖尿病足溃疡管理培训的合格卫生工作者。这可能导致诊断延迟、治疗不充分和患者预后不良。

病人依从性差：

成功治疗糖尿病足溃疡通常需要严格遵守治疗方案，包括伤口护理、血糖控制和生活方式调整。然而，由于各种原因，包括无知、经济问题和心理障碍，某些患者可能难以坚持治疗。

糖尿病盛行率增加：

糖尿病在世界各地变得越来越普遍，增加了糖尿病足溃疡的风险。这给医疗保健系统带来了沉重负担，加剧了资源短缺，并增加了治疗糖尿病足溃疡的需求。

併发症

下肢截肢、坏疽和感染是糖尿病足溃疡可能导致的一些严重后果。这些问题不仅增加医疗费用，而且对患者的生活品质产生重大负面影响。

监理课题：

冗长且昂贵的监管审批程序可能会阻碍糖尿病足溃疡新疗法的开发和商业化。对于希望将新疗法推向市场的公司来说，严格的监管可能是一个问题。

竞争环境：

在竞争激烈的糖尿病足溃疡市场中，许多公司提供各种产品和治疗方法。来自竞争对手的价格竞争会降低利润率和定价能力，特别是对于提供新疗法的公司而言。

Diabetic Foot Ulcers Market size was valued at USD 1.53 Billion in 2023 and is projected to reach USD 3.1 Billion by 2030 , growing at a CAGR of 9.24% during the forecast period 2024-2031. Global Diabetic Foot Ulcers Market Market Drivers The market drivers for the Diabetic Foot Ulcers Market can be influenced by various factors. These may include: Growing Prevalence of Diabetes:

As the incidence of diabetes rises worldwide, so does the prevalence of diabetic foot ulcers. The need for therapies and management alternatives for diabetes is fueled by the growing number of people with the disease and the increased risk of complications such foot ulcers.

Aging Population:

Diabetes and its consequences, such as diabetic foot ulcers, are more common in the aging population. The number of individuals at risk of DFUs rises with population aging, which fuels market expansion.

Technological Advancements:

The management and results of treatment for diabetic foot ulcers are being improved by advances in wound care technology, such as improved dressings, negative pressure wound therapy, and bioengineered skin substitutes. Adoption of these technologies lowers the risk of amputations and improves healing rates, which propels market expansion.

Governmental Programs:

The DFU market is mostly driven by government programs focused at lowering the burden of diabetes and its comorbidities. The need for DFU therapies may rise in response to policies that emphasize diabetes education, prevention, and healthcare service accessibility.

Growing Healthcare Expenditure:

More access to diabetic foot ulcer therapies and management choices is made possible by rising healthcare spending, especially in emerging economies. The DFU market grows as more people and healthcare institutions devote resources to controlling diabetes and its consequences.

Awareness Programs:

By educating people on the value of foot care for diabetic patients, healthcare organizations, patient advocacy groups, and pharmaceutical companies can encourage early detection and treatment of foot ulcers, which will have a beneficial effect on the market. Diabetic foot ulcers can result in serious complications such infections and lower limb amputations, which can lead to significant healthcare costs and financial stress. It becomes essential to address these issues through efficient management and treatment plans, which propels the need for DFU goods and services.

Collaborative Research and Development:

New treatments and interventions for diabetic foot ulcers are being developed as a result of partnerships between pharmaceutical companies, academic institutions, and healthcare providers. These partnerships quicken the tempo of research and development, resulting in the release of novel goods and therapies and the expansion of the market.

Global Diabetic Foot Ulcers Market Restraints

Several factors can act as restraints or challenges for the Diabetic Foot Ulcers Market. These may include:

Expensive Treatment:

Diabetic foot ulcers can be costly to treat because they require ongoing medical consultations, specialist wound care products, and occasionally surgical procedures. Patients may have financial difficulties as a result, especially if their healthcare coverage is limited.

Inadequate Healthcare Infrastructure:

Many areas, particularly in poor nations, lack a sufficient healthcare infrastructure as well as qualified medical personnel with diabetes foot ulcer management training. Delays in diagnosis, insufficient care, and unfavorable patient outcomes may result from this.

Poor Patient Compliance:

Strict adherence to treatment regimens, which include wound care, glucose management, and lifestyle adjustments, is frequently necessary for the successful treatment of diabetic foot ulcers. However, adherence may be difficult for certain patients for a variety of reasons, including ignorance, financial difficulties, or psychological obstacles.

Growing Prevalence of Diabetes:

Diabetes is becoming more commonplace worldwide, which increases the risk of developing diabetic foot ulcers. This puts a heavy load on healthcare systems, making resource shortages worse and raising the need for treatments for diabetic foot ulcers.

Complications:

Lower limb amputation, gangrene, and infection are among the serious consequences that diabetic foot ulcers can lead to. These issues have a substantial negative influence on patients' quality of life in addition to raising healthcare expenses.

Regulatory Challenges:

Long and expensive regulatory approval procedures may impede the development and implementation of novel therapies for diabetic foot ulcers. Strict regulatory regulations could be a problem for businesses looking to launch novel treatments.

Competitive Environment:

A number of businesses are providing a variety of goods and treatments in the fiercely competitive diabetic foot ulcer market. Competitive pricing can reduce profit margins and pricing power, particularly for businesses offering new treatment choices.

Global Diabetic Foot Ulcers Market Segmentation Analysis

The Global Diabetic Foot Ulcers Market is Segmented on the basis of Type of Treatment, Devices, End-users, and Geography.

Diabetic Foot Ulcers Market, By Type of Treatment

Topical Medications:
Includes creams, ointments, and gels applied directly to the ulcer site to promote healing and prevent infection.
Advanced Wound Care Products:
This segment involves specialized dressings, bandages, and wound care devices designed to accelerate healing and maintain a moist wound environment.
Biologics:
Utilizes biological substances such as growth factors, skin substitutes, and stem cell therapy to stimulate tissue regeneration and wound closure.
Hyperbaric Oxygen Therapy (HBOT):
Involves administering oxygen at increased atmospheric pressure to enhance tissue oxygenation and promote healing in non-healing ulcers.

Diabetic Foot Ulcers Market, By Devices

Pressure Relief Devices:
Includes custom orthotics, offloading shoes, and diabetic foot braces aimed at reducing pressure on ulcer-prone areas of the foot.
Wound Debridement Devices:
Instruments and tools used to remove dead or infected tissue from the wound site to facilitate healing.
Negative Pressure Wound Therapy (NPWT):
Involves applying negative pressure to the wound bed through a vacuum system to promote healing and reduce wound size.
Electrical Stimulation Devices:
Utilizes electrical currents to stimulate wound healing and improve blood flow to the affected area.

Diabetic Foot Ulcers Market, By End-users

Hospitals and Clinics:
Facilities providing inpatient and outpatient care for diabetic foot ulcer patients, including wound care clinics and specialized diabetic foot care centers.
Homecare Settings:
Includes products and services tailored for home use, such as self-administered wound care kits and telemedicine consultations.
Research and Academic Institutes:
Institutions engaged in clinical research, development of novel therapies, and academic training related to diabetic foot ulcers.

Diabetic Foot Ulcers Market, By Geography

North America:
Leading region in terms of market share due to high prevalence of diabetes and advanced healthcare infrastructure.
Europe:
Significant market share attributed to increasing diabetic population and growing adoption of advanced wound care products.
Asia-Pacific:
Emerging market with rising diabetes prevalence and improving access to healthcare services driving market growth.
Latin America:
Increasing awareness about diabetic foot care and improving healthcare facilities contributing to market expansion.
Middle East and Africa:
Growing diabetic population and rising healthcare expenditure driving demand for diabetic foot ulcer treatment options.

Key Players

The major players in the Diabetic Foot Ulcers Market are:

3M Co

Smith & Nephew Plc
B. Braun SE
Molnlycke Health Care AB
MiMedx Group Inc
URGO MEDICAL Australia Pty Ltd
Organogenesis Inc

1 INTRODUCTION OF GLOBAL DIABETIC FOOT ULCERS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL DIABETIC FOOT ULCERS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL DIABETIC FOOT ULCERS MARKET, BY TYPE OF TREATMENT

5.1 TOPICAL MEDICATIONS
5.2 ADVANCED WOUND CARE PRODUCTS
5.3 BIOLOGICS
5.4 HYPERBARIC OXYGEN THERAPY (HBOT)

6 GLOBAL DIABETIC FOOT ULCERS MARKET, BY DEVICES

6.1 PRESSURE RELIEF DEVICES
6.2 WOUND DEBRIDEMENT DEVICES
6.3 NEGATIVE PRESSURE WOUND THERAPY (NPWT)
6.4 ELECTRICAL STIMULATION DEVICES

7. GLOBAL DIABETIC FOOT ULCERS MARKET, BY END-USERS

7.1 HOSPITALS AND CLINICS
7.2 HOMECARE SETTINGS
7.3 RESEARCH AND ACADEMIC INSTITUTES

8 GLOBAL DIABETIC FOOT ULCERS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL DIABETIC FOOT ULCERS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Acelity L.P. Inc.
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 B. Braun Melsungen AG
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 BSN Medical GMBH
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Coloplast A/S
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 ConvaTec, Inc.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Medline Industries, Inc.
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Medtronic Plc.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Molnlycke Health Care AB
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Organogenesis, Inc.
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Smith & Nephew Plc.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments